Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
8-K
Delisting risk
confidence 98%
filed 2026-10-23
Item 3.01
Century Casinos received a deficiency notice from Nasdaq on October 19, 2026, for failing to maintain the minimum Market Value of Listed Securities (MVLS) of $35 million required under Nasdaq Listing Rule 5550(b)(2). The company has 180 calendar days until April 19, 2027, to regain compliance or face delisting. This is a classic delisting-risk disclosure under Item 3.01, with explicit language that "if the Company does not regain compliance by the Compliance Date, the Staff will provide written notification that the Company's common stock is subject to delisting."
View raw filing on EDGAR →
8-K
Delisting risk
confidence 94%
filed 2026-10-23
Item 3.01
Medicus Pharma received a delisting determination letter from Nasdaq on October 20, 2026, for failure to maintain the $1.00 minimum bid price requirement, but subsequently regained compliance on October 23, 2026. The company faces ongoing delisting risk and cannot assure future compliance with Nasdaq's continued listing standards.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 92%
filed 2026-10-23
Item 7.01
T3 Defense received a Nasdaq notice on August 20, 2026 that it failed to maintain the minimum $10 million stockholders' equity requirement under Nasdaq Listing Rule 5450(b)(1)(A), creating delisting risk. Although the company claims to have regained compliance as of September 30, 2026 through warrant exercises that eliminated the liability-classified warrant position, the disclosure explicitly states "if at the time of its next periodic report the Company does not evidence compliance, the Company may be subject to delisting" and "There can be no assurance that Nasdaq will determine that the Company has regained compliance." This is a material delisting-risk disclosure, not a resolved delisting matter.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 95%
filed 2026-10-23
Item 8.01
The disclosure centers on Alaunos' delisting status from Nasdaq. The Company received a delisting notice on October 5, 2026 for non-compliance with the Stockholders' Equity Requirement (minimum $2.5M), timely requested a hearing, but then regained compliance following a private placement on October 14, 2026. Nasdaq confirmed compliance on October 22, 2026, cancelling the delisting hearing and allowing continued listing. This is a material resolution of a delisting risk that directly affects the registrant's continued trading status.
View raw filing on EDGAR →
6-K
Delisting risk
confidence 92%
filed 2026-10-23
EX-99.1
The press release announces that Founder Group Limited has regained compliance with Nasdaq's minimum publicly held shares requirement (500,000 shares) under Listing Rule 5550(a)(4), after receiving a non-compliance notice on September 16, 2026. While the announcement is positive (compliance regained), it discloses a material delisting risk event—the prior non-compliance that threatened continued listing—and its resolution. This is material to investors as it directly affects the registrant's ability to maintain its Nasdaq listing.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 95%
filed 2026-10-23
Item 8.01
Citius Oncology received formal notice from Nasdaq granting an extension through April 19, 2027 to comply with the $1.00 per share bid price requirement under Nasdaq Listing Rule 5550(a)(2). The disclosure explicitly states that if the company fails to regain compliance by that date, Nasdaq will provide written notice that the stock is subject to delisting. This is a classic delisting-risk disclosure under Item 8.01, with a specific compliance deadline and clear consequences for non-compliance.
View raw filing on EDGAR →
6-K
Delisting risk
confidence 95%
filed 2026-10-23
EX-99.1
Gix Internet announced a voluntary delisting of its ordinary shares from the Tel Aviv Stock Exchange (TASE), with the last trading day expected January 25, 2027, and delisting on or about January 27, 2027. While this is a voluntary delisting (not a failure to meet listing standards), it represents a material change in the registrant's listing status and trading venue consolidation. The company will continue trading exclusively on Nasdaq, but the removal from TASE is a significant corporate action affecting shareholder liquidity and market access.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 95%
filed 2026-10-23
The filing discloses Item 3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule. Polar Power received a deficiency letter from Nasdaq on May 1, 2026, for failing to maintain the minimum $2.5 million stockholders' equity requirement under Nasdaq Listing Rule 5550(b)(1), and was granted an extension until October 28, 2026, to demonstrate compliance. The company now claims to have regained compliance through multiple equity-raising transactions, but Nasdaq retains discretion to monitor and potentially delist if compliance is not maintained. This is a core delisting-risk disclosure.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 98%
filed 2026-10-23
Laser Photonics received a Nasdaq notification on October 20, 2026, that it failed to maintain the minimum bid price requirement of $1.00 per share for 30 consecutive business days under Nasdaq Listing Rule 5550(a)(2). The company has 180 calendar days (until April 19, 2027) to regain compliance or face delisting. This is a classic delisting-risk disclosure under Item 3.01, materially affecting investor assessment of the registrant's continued listing status.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 98%
filed 2026-10-23
Item 3.01
The filing discloses that Nasdaq notified Dragonfly on August 20, 2026, of non-compliance with the minimum stockholders' equity requirement (Rule 5550(b)(1)), with stockholders' equity of $(184,000) versus the required $2.5 million minimum. Although the company received an extension through December 31, 2026, to regain compliance, the filing explicitly states that failure to evidence compliance by that date "may be subject to delisting" and that the Staff will provide written notification of delisting if the company does not satisfy the extension terms. This is a classic delisting-risk disclosure under Item 3.01.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 95%
filed 2026-10-23
The filing discloses a written notice from Nasdaq on October 20, 2026, indicating that the Company's warrants are no longer in compliance with Nasdaq Listing Rule 5452(b)(C) because the aggregate market value of outstanding warrants fell below the required $1 million threshold. The Company has 45 calendar days to submit a compliance plan and up to 180 days to regain compliance, with explicit acknowledgment that failure to comply could result in delisting of the warrants. This is a classic delisting-risk disclosure under Item 3.01.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 98%
filed 2026-10-23
Item 3.01
Akebia received a deficiency notice from Nasdaq on October 21, 2026, for failing to maintain the minimum $1.00 bid price requirement under Nasdaq Listing Rule 5550(a)(2). The company has 180 calendar days (until April 19, 2027) to regain compliance, with potential delisting if it fails to do so. This is a classic delisting-risk disclosure under Item 3.01, materially threatening the company's continued listing status.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 97%
filed 2026-10-23
Item 3.01
STEM received a formal non-compliance letter from NYSE on October 20, 2026, for failing to maintain the required average global market capitalization of $50 million and stockholders' equity of $50 million under Section 802.01B. The company must submit a business plan within 45 days demonstrating compliance within 18 months or face delisting.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 98%
filed 2026-10-23
Item 3.01
Innventure received a Nasdaq notice on October 23, 2026 that it failed to maintain the minimum bid price of $1.00 per share for 30 consecutive business days, triggering a delisting notice under Nasdaq Listing Rule 5450(a)(1). The company has been granted an initial 180-day compliance period (until April 21, 2027) to regain compliance, with a potential additional 180-day period if it transfers to the Nasdaq Capital Market. This is a classic delisting-risk disclosure under Item 3.01, materially affecting investor assessment of the registrant's continued listing status.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 98%
filed 2026-10-22
Item 3.01
Nasdaq has initiated delisting procedures against Globa Terra Acquisition Corp for failure to complete a business combination within the required 15-month timeframe (or extended periods). The company received a Staff Determination on October 16, 2026, notifying it of non-compliance with Nasdaq IM-5101-2(b). Trading suspension is scheduled for October 27, 2026, unless the company successfully appeals to a Nasdaq Hearing Panel by October 23, 2026. This is a direct notice of delisting risk and failure to satisfy continued listing standards, the core subject matter of Item 3.01.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 98%
filed 2026-10-22
Item 3.01
Atlantic American Corporation received a Staff Delisting Determination from Nasdaq on October 16, 2026, initiating a process to delist the Company's common stock due to failure to timely file required periodic reports (Form 10-K and Form 10-Qs) in violation of Nasdaq Listing Rule 5250(c)(1). The Company intends to appeal and request a hearing before the Nasdaq Hearings Panel, with an automatic 15-day stay of trading suspension upon filing the hearing request. This is a clear delisting risk disclosure under Item 3.01.
View raw filing on EDGAR →
6-K
Delisting risk
confidence 95%
filed 2026-10-22
The SEC announced a temporary suspension of trading in TJGC Group Limited's securities pursuant to Section 12(k) of the Securities Exchange Act of 1934, effective October 15–28, 2026. While temporary, a trading suspension is a direct precursor to delisting and represents a material threat to the registrant's continued listing status and market access. The company's acknowledgment that it has "no knowledge of and is not connected to any alleged price manipulation activity" does not diminish the materiality of the suspension order itself.
View raw filing on EDGAR →
6-K
Delisting risk
confidence 92%
filed 2026-10-22
EX-99.1
The press release announces that Yimutian has regained compliance with Nasdaq's minimum stockholders' equity requirement of US$2.5 million after previously being out of compliance. While framed positively as a "compliance letter," the disclosure reveals the Company was subject to a delisting threat, is now under mandatory panel monitoring for one year, and faces automatic delisting without cure rights if it falls out of compliance again during that period. This is material to investors as it reflects prior listing jeopardy and ongoing heightened delisting risk under Nasdaq Listing Rule 5815(d)(4)(B).
View raw filing on EDGAR →
6-K
Delisting risk
confidence 95%
filed 2026-10-22
EX-99.1
The press release announces that Linkage Global has regained compliance with Nasdaq's minimum bid price requirement (Nasdaq Listing Rule 5550(a)(2)) after previously falling out of compliance on June 3, 2026. The Company was required to maintain a closing bid price of at least $1.00 per share for 10 consecutive business days to cure the deficiency; it achieved 20 consecutive business days at or above that threshold from September 21 through October 16, 2026, and Nasdaq has now closed the matter. This is a material delisting-risk disclosure because it directly addresses a continued listing qualification issue that, if unresolved, would have resulted in delisting from the Nasdaq Capital Market.
View raw filing on EDGAR →
6-K
Delisting risk
confidence 92%
filed 2026-10-22
EX-99.1
The press release announces a 1-for-100 share consolidation explicitly undertaken "to enable the Company to regain compliance with Nasdaq Marketplace Rule 5550(a)(2) and maintain its listing on the Nasdaq Capital Market." This disclosure directly addresses a failure to satisfy a continued listing rule and the remedial action taken to avoid delisting, which is material to investors assessing the registrant's exchange listing status.
View raw filing on EDGAR →
6-K
Delisting risk
confidence 95%
filed 2026-10-22
The 6-K discloses a Nasdaq Hearings Panel decision on October 7, 2026, denying MaxsMaking's request to reinstate trading and ordering delisting of the Company's securities. The Panel cited trading activity indicative of potential manipulation, insufficient liquidity, and inadequate public float. Trading has been halted since December 2, 2025, and the Company's only remaining recourse is a request for review by the Listing and Hearing Review Council, which does not stay the suspension. This is a material delisting event under Item 3.01 equivalent.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 95%
filed 2026-10-22
The filing discloses Item 3.01 notice of delisting risk: Nasdaq determined the Company's warrants failed to maintain the required $1 million aggregate market value under Listing Rule 5452(b)(C), and while an extension to February 23, 2027 was granted, failure to regain compliance by that date will result in delisting notification. This is a material disclosure of continued listing jeopardy.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 97%
filed 2026-10-22
Item 3.01
SenesTech received formal notification from Nasdaq on October 20, 2026, that its common stock failed to meet the minimum bid price requirement (closing below $1.00 per share for 30 consecutive business days) under Nasdaq Listing Rule 5550(a)(2). The company has 180 calendar days until April 19, 2027, to regain compliance or face delisting.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 97%
filed 2026-10-22
Item 3.01
Lunai Bioworks received a Nasdaq determination on October 21, 2026, that it no longer complies with Listing Rule 5550(b)(1) due to a stockholders' deficit of $(9,024,946), failing to meet minimum equity requirements. The Company's Board approved voluntary withdrawal from Nasdaq listing on October 22, 2026, with trading suspension expected October 30, 2026, and delisting effective November 12, 2026.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 95%
filed 2026-10-21
Item 3.01
NYSE Regulation issued a public warning letter on October 19, 2026 citing violations of Section 401(a) disclosure requirements and explicitly warning that any future violation will result in immediate suspension and commencement of delisting proceedings.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 95%
filed 2026-10-21
Item 3.01
The filing discloses Alaunos' receipt of a Nasdaq deficiency notice on April 9, 2026 for failure to maintain the $2.5 million stockholders' equity requirement, followed by a delisting notice on October 5, 2026 due to continued non-compliance. Although the Company claims to have regained compliance through the October 14, 2026 financing ($350 million in proceeds), the disclosure explicitly states that Nasdaq will continue monitoring compliance and "if at the time of the filing of the Company's Annual Report on Form 10-K for the fiscal year ending December 31, 2026 the Company does not evidence compliance, the Company may be subject to delisting." This is a classic delisting-risk disclosure under Item 3.01, with material uncertainty about sustained compliance.
View raw filing on EDGAR →
6-K
Delisting risk
confidence 92%
filed 2026-10-21
EX-99.1
The press release announces a 1-for-20 reverse stock split effective October 26, 2026, explicitly stating the action is "primarily intended to enable the Company to regain compliance with the minimum bid price requirement for continued listing on the Nasdaq Capital Market." The disclosure acknowledges delisting risk by noting "there can be no assurance that the Company will regain compliance with such requirement within the applicable compliance period or maintain compliance with Nasdaq's continued listing requirement thereafter," which is a material disclosure of compliance failure and delisting threat.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 95%
filed 2026-10-21
The filing discloses that Vivos received a deficiency notice from Nasdaq in April 2026 for failing to meet continued listing requirements (minimum $2.5M stockholders' equity, $35M market value, or $500K net income). On October 20, 2026, Nasdaq confirmed compliance with the stockholders' equity requirement following the SOD acquisition, but explicitly warned that "if the Company fails to evidence compliance upon the filing of its next periodic report, the Company may be subject to delisting." This is a material delisting risk disclosure under Item 8.01, as the company remains conditionally compliant and faces imminent delisting if it fails to maintain the equity threshold.
View raw filing on EDGAR →
6-K
Delisting risk
confidence 95%
filed 2026-10-21
EX-99.1
Genenta Science received a Nasdaq notification on October 16, 2026, that it failed to maintain the minimum bid price of $1.00 per share for 30 consecutive business days. The company has been given 180 calendar days (until April 14, 2027) to regain compliance or face delisting. This is a classic delisting-risk disclosure under Item 3.01 equivalent, as it directly threatens the company's continued listing on Nasdaq Capital Market.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 92%
filed 2026-10-21
Item 8.01
The filing discloses that TruGolf failed to meet Nasdaq's minimum stockholders' equity requirement of $2,500,000 (actual equity was $2,060,281 as of June 30, 2026), triggering a delisting notice. Although the company believes it has regained compliance following the Polymath acquisition and financing, Nasdaq explicitly warned that "if at the time of its next periodic report, the Company does not evidence compliance, that it may be subject to delisting." This is a material delisting risk disclosure under Item 3.01 principles, even though filed under Item 8.01.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 95%
filed 2026-10-21
Item 3.01
Direct Digital Holdings voluntarily withdrew its Class A common stock from Nasdaq listing and deregistered under Section 12(b) of the Exchange Act following a Nasdaq delisting determination on October 1, 2026 for failure to comply with Listing Rule 5550(b)(1). Delisting is expected to become effective November 12, 2026, with Form 15 deregistration to follow.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 99%
filed 2026-10-20
Item 3.01
XWELL received a notice from Nasdaq on October 7, 2026, that its common stock failed to maintain the minimum bid price of $1.00 per share required under Nasdaq Listing Rule 5550(a)(2). The company has been granted a 180-calendar-day compliance period until April 5, 2027, to regain compliance, with the explicit warning that failure to do so will result in delisting. This is a textbook delisting-risk disclosure under Item 3.01.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 95%
filed 2026-10-20
Item 3.01
Following the merger consummation, Beazer Homes requested NYSE suspension of trading and filed Form 25 to delist and deregister shares under Section 12(b) of the Exchange Act, with delisting effective 10 days after Form 25 filing.
View raw filing on EDGAR →
6-K
Delisting risk
confidence 92%
filed 2026-10-20
The Company approved a reverse stock split (2-for-5) effective October 22, 2026, explicitly stated as "intended for the Company to regain compliance with a minimum bid price of $1.00 per share for continued listing on Nasdaq, as set forth in Nasdaq Listing Rule 5550(a)(2)." This disclosure reveals the Company was in violation of Nasdaq's minimum bid price requirement and took corrective action to avoid delisting—a material event affecting investor assessment of listing status and compliance risk.
View raw filing on EDGAR →
6-K
Delisting risk
confidence 95%
filed 2026-10-20
On October 15, 2026, Kandal M Venture Limited received a Nasdaq deficiency letter notifying the Company that it no longer meets the continued listing requirement under Nasdaq Listing Rule 5550(a)(4) regarding minimum publicly held shares (500,000). The Company has until November 30, 2026 to submit a compliance plan, with explicit acknowledgment that there is no assurance of regaining compliance. This is a classic delisting-risk disclosure under Item 3.01.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 94%
filed 2026-10-20
Item 8.01
DataMeds AI announced on October 20, 2026 that it has regained compliance with Nasdaq Listing Rule 5550(b)(1) after receiving a delisting notice on April 13, 2026 for failure to maintain the required minimum stockholders' equity of $2.5 million. The company has remediated the deficiency as of October 19, 2026, but faces continued delisting risk if it fails to evidence compliance upon filing its next periodic report.
View raw filing on EDGAR →
6-K
Delisting risk
confidence 95%
filed 2026-10-20
EX-99.1
Dogness received a Nasdaq deficiency notification on October 19, 2026, for failure to maintain the minimum bid price requirement (closing bid below $1.00 for 30 consecutive business days). The company has 180 calendar days until April 19, 2027, to regain compliance or faces potential delisting. This is a classic delisting-risk disclosure under Item 3.01 equivalent, materially affecting the registrant's continued listing status and investor assessment.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 95%
filed 2026-10-20
The filing discloses that SHF Holdings received notice from Nasdaq on October 20, 2026 that it has an additional 180-day compliance period (until April 19, 2027) to regain compliance with the minimum $1.00 bid price requirement under Nasdaq Listing Rule 5550(a)(2). This follows an initial 180-day period that expired October 19, 2026. Item 3.01 explicitly states that if the company does not regain compliance by April 19, 2027, "the Staff will provide written notification to the Company that its securities will be subject to delisting." This is a clear delisting risk disclosure.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 98%
filed 2026-10-20
The filing discloses a Staff Determination from Nasdaq on October 14, 2026, notifying the Company that it has failed to regain compliance with Nasdaq Listing Rule 5250(c)(1) due to non-filing of its Q2 2026 Form 10-Q. The Staff Determination explicitly states that trading will be suspended on October 23, 2026, and Nasdaq will file a Form 25-NSE to remove the Company's securities from listing unless the Company requests a hearing. This is a textbook delisting-risk disclosure under Item 3.01, with the Company facing imminent suspension and delisting absent successful appeal to the Nasdaq Hearings Panel.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 94%
filed 2026-10-20
Item 3.01
Hilton announced its voluntary withdrawal from NYSE listing and transfer to Nasdaq, with trading ending on NYSE at market close November 4, 2026, and commencing on Nasdaq November 5, 2026.
View raw filing on EDGAR →
6-K
Delisting risk
confidence 92%
filed 2026-10-19
EX-99.1
The exhibit announces Belite Bio's uplisting from the Nasdaq Capital Market to the Nasdaq Global Select Market, effective October 19, 2026. While framed positively as a "milestone," this is a material transfer of listing venue that reflects the company's achievement of compliance with the higher tier's "more stringent financial and liquidity standards." The reverse of this event—failure to maintain listing standards—would constitute delisting risk; the uplisting itself is the favorable resolution of that risk and is material to investors assessing the company's market standing and capital access.
View raw filing on EDGAR →
6-K
Delisting risk
confidence 92%
filed 2026-10-19
EX-99.1
QTREX announced on October 19, 2026 that it has regained compliance with Nasdaq's minimum bid price requirement (Listing Rule 5550(a)(2)) after the closing bid price of its ordinary shares reached $1.00 or greater for 10 consecutive business days (October 2–15, 2026). This disclosure directly addresses a delisting risk — the company was previously non-compliant with a continued listing standard and has now cured that deficiency. The announcement confirms Nasdaq has closed the matter and the shares remain listed on The Nasdaq Capital Market.
View raw filing on EDGAR →
6-K
Delisting risk
confidence 95%
filed 2026-10-19
EX-99.1
LexinFintech received a written notice from Nasdaq on October 14, 2026 indicating non-compliance with the $1.00 minimum bid price requirement under Nasdaq Listing Rule 5450(a)(1). The company has 180 calendar days (until April 12, 2027) to regain compliance, and if it fails to do so, "Nasdaq will initiate delisting proceedings." This is a classic delisting-risk disclosure under Item 3.01 equivalent, as the company faces potential removal from the Nasdaq Global Select Market if it cannot restore its stock price above $1.00 per ADS for ten consecutive business days.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 95%
filed 2026-10-19
Item 3.01
Following the completion of the merger, ACV Auctions notified the NYSE of the consummation and requested suspension of trading and delisting of ACV Stock via Form 25 Notification of Removal from Listing, with intent to file Form 15 to terminate registration under Section 12(g) and suspend reporting obligations.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 95%
filed 2026-10-19
The filing's primary disclosure is Item 3.01, which reports that Nasdaq has issued a Staff Delisting Determination to suspend trading and delist Stardust Power's securities effective October 23, 2026, triggered by the stock closing at $0.10 or less for ten consecutive trading days. This is a terminal delisting event, not merely a notice of risk. While Item 5.02 reports the CFO's resignation and Item 8.01 discusses potential strategic alternatives, the dominant and most material event is the imminent delisting from Nasdaq Capital Market.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 92%
filed 2026-10-19
Item 8.01
PLAYSTUDIOS received written notification from Nasdaq on October 15, 2026, confirming regained compliance with the $1.00 minimum bid price requirement after previously receiving a non-compliance notice on November 5, 2025. The company executed a 1-for-10 reverse stock split on September 30, 2026, to remedy the deficiency. This disclosure directly addresses delisting risk—the resolution of a material listing qualification failure that threatened continued trading on Nasdaq Capital Market.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 95%
filed 2026-09-29
Item 3.01
Elme Communities provided notice of voluntary delisting to the NYSE on September 29, 2026, in connection with the company's intended dissolution; the company anticipates filing a Form 25 on October 26, 2026, with the last day of trading expected November 5, 2026.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 94%
filed 2026-09-29
Item 3.01
Liminatus Pharma regained compliance with Nasdaq's minimum bid price rule (Listing Rule 5550(a)(2)) following a reverse stock split and transfer to The Nasdaq Capital Market. The company had previously received a notice of non-compliance on January 15, 2026, was transferred to Nasdaq Capital Market on August 4, 2026, and received notice of regained compliance on September 24, 2026.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 98%
filed 2026-09-29
Item 3.01
Maison Solutions received a formal notification from Nasdaq on September 23, 2026, stating non-compliance with Listing Rule 5250(c)(1) due to failure to timely file its Form 10-Q and Form 10-K. The company has until October 19, 2026 to submit a compliance plan, with potential delisting if the plan is not accepted or compliance is not achieved by February 9, 2027.
View raw filing on EDGAR →
6-K
Delisting risk
confidence 90%
filed 2026-09-29
EX-99.1
Enlivex disclosed that its ordinary shares are trading below the Nasdaq minimum bid price of $1.00 and face imminent delisting risk if the price remains below $1.00 for 30 consecutive trading days through October 21, 2026. The Company is seeking shareholder approval for a 1-for-16 reverse share split and amendment to its Articles of Association to address the delisting risk and restore compliance with Nasdaq listing standards.
View raw filing on EDGAR →